OTCMKTS:BMXMF

bioMérieux Stock Forecast, Price & News

$108.75

+0.85 (+0.79 %)

(As of 06/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$107.91

▼

$108.81

50-Day Range

$105.65

▼

$137.09

52-Week Range

$105.65

▼

$170.55

Volume6 shs

Average Volume166 shs

Market Capitalization$12.87 billion

P/E Ratio27.88

Dividend YieldN/A

Beta-0.2

30 days | 90 days | 365 days | Advanced Chart

Receive BMXMF News and Ratings via Email

Sign-up to receive the latest news and ratings for bioMérieux and its competitors with MarketBeat's FREE daily newsletter.

About bioMérieux

bioMÃ©rieux S.A. develops and produces in vitro diagnostic solutions for private and hospital laboratories for the diagnosis of infectious diseases. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. The company was formerly known as B-D MÃ©rieux. bioMÃ©rieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMÃ©rieux S.A. is a subsidiary of Institut MÃ©rieux SA.

bioMérieux (OTCMKTS:BMXMF) Reaches New 12-Month Low at $105.65
June 18, 2021 | americanbankingnews.com

bioMérieux (OTCMKTS:BMXMF) Reaches New 52-Week Low at $108.55
June 11, 2021 | americanbankingnews.com

Berenberg Bank Upgrades bioMérieux (OTCMKTS:BMXMF) to Hold
June 11, 2021 | americanbankingnews.com

bioMérieux (OTCMKTS:BMXMF) Hits New 12-Month Low at $109.03
June 4, 2021 | americanbankingnews.com

bioMérieux S.A. (OTCMKTS:BMXMF) Short Interest Up 23.3% in May
June 4, 2021 | americanbankingnews.com

bioMérieux S.A. (OTCMKTS:BMXMF) Given Average Rating of "Hold" by Brokerages
June 3, 2021 | americanbankingnews.com

bioMérieux (OTCMKTS:BMXMF) Trading 0.4% Higher
June 1, 2021 | americanbankingnews.com

bioMérieux - 2020 Financial Results
March 23, 2021 | finanznachrichten.de

bioMérieux - First-Half 2020 Results
September 29, 2020 | finanznachrichten.de

French labs show how global supply bottlenecks thwart effort to ramp up testing
September 27, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BMXMF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.biomerieux.com
Phone33-4-78-87-20-00
Employees12,000
Year FoundedN/A

Sales & Book Value

Annual Sales$3.56 billion
Price / Sales3.61
Cash Flow$5.95 per share
Price / Cash Flow18.28
Book Value$23.95 per share
Price / Book4.54

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares118,361,000
Market Cap$12.87 billion
Next Earnings Date6/23/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.63 out of 5 stars

Medical Sector

1398th out of 2,105 stocks

Private Households Industry

249th out of 381 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for bioMérieux.

2.5 Community Rank

Outperform Votes
bioMérieux has received 105 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
bioMérieux has received 107 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
bioMérieux has received 50.47% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about bioMérieux and other stocks. Vote “Outperform” if you believe BMXMF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMXMF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
bioMérieux does not currently pay a dividend.
Dividend Growth
bioMérieux does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, bioMérieux insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for bioMérieux are expected to decrease by -7.97% in the coming year, from $4.64 to $4.27 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of bioMérieux is 27.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.55.
Price to Earnings Ratio vs. Sector
The P/E ratio of bioMérieux is 27.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 43.83.
Price to Book Value per Share Ratio
bioMérieux has a P/B Ratio of 4.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

bioMérieux (OTCMKTS:BMXMF) Frequently Asked Questions

Is bioMérieux a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bioMérieux in the last year. There are currently 2 sell ratings, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" bioMérieux stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMXMF, but not buy additional shares or sell existing shares.
View analyst ratings for bioMérieux or view top-rated stocks.

What stocks does MarketBeat like better than bioMérieux?

Wall Street analysts have given bioMérieux a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but bioMérieux wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting bioMérieux?

bioMérieux saw a increase in short interest in May. As of May 14th, there was short interest totaling 604,100 shares, an increase of 23.3% from the April 29th total of 489,900 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is currently 6,041.0 days.
View bioMérieux's Short Interest.

When is bioMérieux's next earnings date?

bioMérieux is scheduled to release its next quarterly earnings announcement on Wednesday, June 23rd 2021.
View our earnings forecast for bioMérieux.

How has bioMérieux's stock been impacted by COVID-19?

bioMérieux's stock was trading at $91.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BMXMF shares have increased by 18.9% and is now trading at $108.75.
View which stocks have been most impacted by COVID-19.

Who are bioMérieux's key executives?

bioMérieux's management team includes the following people:

Mr. Alexandre Merieux, Chairman & CEO (Age 47, Pay $1.3M)
Mr. Frederic Beseme, Employee Director & Head of CSR (Age 65, Pay $30.41k)
Mr. Guillaume Bouhours, Exec. VP of Purchasing and Information Systems & CFO (Age 45)
Mr. Pierre Boulud, Chief Operating Officer (Age 50)
Sylvain Morgeau, Investor Relations
Ms. Esther Wick, Exec. VP of Legal, Intellectual Property & Compliance
Ms. Valerie Leylde, Exec. VP of HR & Communications
Mr. FranÃ§ois Lacoste, Exec. VP of R&D
Mr. Mark Miller, Exec. VP & Chief Medical Officer
Mr. Pierre Charbonnier, Exec. VP of Quality, Manufacturing & Supply Chain

Who are some of bioMérieux's key competitors?

Some companies that are related to bioMérieux include The Swatch Group (SWGAY), Oriental Land (OLCLY), HOYA (HOCPY), Bank of Communications (BCMXY), Jardine Matheson (JMHLY), Sun Hung Kai Properties (SUHJY), ITOCHU (ITOCY), China Shenhua Energy (CSUAY), Kuehne + Nagel International (KHNGY), Seven & i (SVNDY), Henkel AG & Co. KGaA (HENKY), Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (MURGY), SMC (SMCAY), Compass Group (CMPGY) and Fujitsu (FJTSY).
View all of BMXMF's competitors.

What is bioMérieux's stock symbol?

bioMérieux trades on the OTCMKTS under the ticker symbol "BMXMF."

How do I buy shares of bioMérieux?

Shares of BMXMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bioMérieux's stock price today?

One share of BMXMF stock can currently be purchased for approximately $108.75.

How much money does bioMérieux make?

bioMérieux has a market capitalization of $12.87 billion and generates $3.56 billion in revenue each year. The company earns $461.95 million in net income (profit) each year or $3.90 on an earnings per share basis.

How many employees does bioMérieux have?

bioMérieux employs 12,000 workers across the globe.

What is bioMérieux's official website?

The official website for bioMérieux is www.biomerieux.com.

Where are bioMérieux's headquarters?

bioMérieux is headquartered at 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280.

How can I contact bioMérieux?

bioMérieux's mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The company can be reached via phone at 33-4-78-87-20-00 or via email at [email protected]

This page was last updated on 6/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here